Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Testori

Showing results (91-100 of 153) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 30, 2015
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guidelineAlexander Stratigos, Claus Garbe, Celeste Lebbe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 25, 2015
EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanomaChristina Bluemel, Ken Herrmann, Francesco Giammarile, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)Antonia Busse, Jérôme Rapion, Alberto Fusi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2009
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)Alberto Fusi, Sandra Collette, Antonia Busse, et al.
Genes|September 5, 2019
Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart DiseaseAlessandro Testori, Vito A Lasorsa, Flora Cimmino, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2011
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Alexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Annals of Surgical Oncology|October 1, 2005
Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunkGianluca Lazzaro, Roberta Lazzari, Giuseppe Pelosi, et al.
Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.
Lancet (London, England)|October 4, 2005
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialAlexander M M Eggermont, Stefan Suciu, Rona MacKie, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 16, 2014
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programmeMaresa Altomonte, Anna Di Giacomo, Paola Queirolo, et al.
Pageof 16

Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|July 30, 2015
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guidelineAlexander Stratigos, Claus Garbe, Celeste Lebbe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 25, 2015
EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanomaChristina Bluemel, Ken Herrmann, Francesco Giammarile, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)Antonia Busse, Jérôme Rapion, Alberto Fusi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2009
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)Alberto Fusi, Sandra Collette, Antonia Busse, et al.
Genes|September 5, 2019
Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart DiseaseAlessandro Testori, Vito A Lasorsa, Flora Cimmino, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2011
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Alexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Annals of Surgical Oncology|October 1, 2005
Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunkGianluca Lazzaro, Roberta Lazzari, Giuseppe Pelosi, et al.
Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.
Lancet (London, England)|October 4, 2005
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialAlexander M M Eggermont, Stefan Suciu, Rona MacKie, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 16, 2014
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programmeMaresa Altomonte, Anna Di Giacomo, Paola Queirolo, et al.
Pageof 16